Loading
A phase 2/3 trial of docetaxel, doxorubicin, epirubicin, cyclophosphamide and other drugs in triple-negative breast cancer, run by Fudan University, active but no longer recruiting.
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature is a phase 2/3, randomised interventional study registered as NCT02641847 by Fudan University, with a registry enrolment figure of 503 participants, started 2016-01 and due to reach its primary completion in 2023-12. Interventions recorded: docetaxel; doxorubicin or epirubicin; cyclophosphamide; gemcitabine; cisplatin. Conditions listed: Triple Negative Breast Cancer; Breast Cancer. Triple-negative eligibility wording from the registry: "Triple negative breast cancer confirmed by pathology". Sites: China. No results are recorded here; the registry entry is the source.
Shares Epirubicin, Docetaxel, Cyclophosphamide, Early triple-negative breast cancer and the tag tnbc-deep-dive.
Shares Epirubicin, Docetaxel, Cyclophosphamide, Early triple-negative breast cancer and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Docetaxel, Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Gemcitabine and the tag tnbc-deep-dive.
Shares Epirubicin, Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer and the tag tnbc-deep-dive.
Shares Cyclophosphamide, Doxorubicin, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.